

Greater transparency needed in publishing information from clinical trials

January 29 2013

An initiative from the drugs regulator, the European Medicines Agency, to commit to releasing all of the information from clinical trials once the marketing authorization process has ended, which has been greeted with cautious optimism by proponents of access to data but with much less enthusiasm by the pharmaceutical industry, sparks an interesting debate on the role of medical journals in publishing drug data, according to the Editors of *PLOS Medicine*.

Writing in an Editorial, the Editors state: "As 2013 begins, it is clear that critical times lie ahead for the publishing of [clinical trials](#), which may define the relationship between [pharmaceutical companies](#) and the public for many years to come."

The Editors argue: "It is no longer going to be the case, if it ever was, that a trial report published in a journal will be sufficient as the record of a trial—and if journals are not careful, such reports will become unnecessary as well."

The Editors continue: "So in addition to this being a critical time in the relationship of pharmaceutical companies to society in general, it seems that this is a good time to renegotiate the relationship between pharmaceutical companies and [medical journals](#)."

As data become more available for reanalysis, the Editors explain that report of a trial sanctioned by the pharmaceutical company and published in a journal will no longer be considered the definitive report

of the trial. Instead, this report will become just one part of the large volume of information available around a trial, to be considered in conjunction with all analyses and data.

Over the course of 2013 as EMA defines the terms of reference for the release of data the importance of journal articles' reports of a trial will change. According to the Editors, "Some journals will find this harder to adjust to than others, especially those whose business model is heavily dependent on reprints of pharmaceutical companies' versions of trial reports."

More information: The *PLOS Medicine* Editors (2013) Getting More Generous with the Truth: Clinical Trial Reporting in 2013 and Beyond. *PLoS Med* 10(1): e1001379. [doi:10.1371/journal.pmed.1001379](https://doi.org/10.1371/journal.pmed.1001379)

Funding: The authors are each paid a salary by the Public Library of Science, and they wrote this editorial during their salaried time.

Provided by Public Library of Science

Citation: Greater transparency needed in publishing information from clinical trials (2013, January 29) retrieved 20 April 2024 from <https://medicalxpress.com/news/2013-01-greater-transparency-publishing-clinical-trials.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--